Recurrent Episodes of Hypokalaemia during Treatment with Inhaled Beta-2 Agonist Revealing Gitelman Syndrome, an Uncommon Clinical Entity
Authors:
Open Access
- 20 October 2022
- journal article
- research article
- Published by SMC Media in European Journal of Case Reports in Internal Medicine
- Vol. 9 (10) , 003605
Abstract
A 28-year-old female patient was hospitalized for mild–moderate hypokalaemia which was persistent despite discontinuation of beta-2 agonist bronchodilator treatment. Her past medical history was relevant for two episodes of severe hypokalaemia after active inhaled beta-2 agonist treatment for asthma crisis. Investigations revealed increased potassium in spot urine with a transtubular potassium gradient <4. A 24-hour urine analysis showed hypophosphaturia, hypocalciuria, hypomagnesuria and normal urine prostaglandins in favour of Gitelman syndrome. Oral potassium supplementation was started and genetic studies were recommended.Keywords
This publication has 5 references indexed in Scilit:
- New SLC12A3 disease causative mutation of Gitelman’s syndromeWorld Journal of Nephrology, 2016
- Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutationsWorld Journal of Methodology, 2015
- Thyrotoxic periodic paralysis triggered by β2- adrenergic bronchodilatorsCanadian Journal of Emergency Medicine, 2014
- Gitelman syndromeOrphanet Journal of Rare Diseases, 2008
- [Clinical variability of Gitelman's syndrome].2006